Integra LifeSciences Holdings Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 2/6
Integra LifeSciences Holdings hat ein Gesamteigenkapital von $1.6B und eine Gesamtverschuldung von $1.9B, wodurch sich der Verschuldungsgrad auf 116.3% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $4.1B bzw. $2.5B. Integra LifeSciences Holdings Das EBIT des Unternehmens beträgt $239.7M, so dass der Zinsdeckungsgrad 6.9 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $677.3M.
Wichtige Informationen
116.3%
Verhältnis von Schulden zu Eigenkapital
US$1.86b
Verschuldung
| Zinsdeckungsgrad | 6.9x |
| Bargeld | US$677.29m |
| Eigenkapital | US$1.60b |
| Gesamtverbindlichkeiten | US$2.48b |
| Gesamtvermögen | US$4.08b |
Jüngste Berichte zur Finanzlage
We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11
Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Oct 05Recent updates
Integra LifeSciences Still Underperforming As Manufacturing Issues Linger
Jun 21Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price
May 28Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled
Feb 27We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jan 14Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings
Dec 31Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?
Dec 03Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns
Oct 24Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 22Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?
Feb 27Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Feb 02We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return
Dec 21When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Dec 08Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 42% Discount?
Oct 19We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Oct 05Integra LifeSciences: Wide Dislocation In Fundamentals Vs. Market Value
Sep 13Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 06FDA labels recall of intracranial pressure monitors by Integra as most serious
Aug 31Integra Lifesciences voluntarily recalls pressure monitors, lowers revenue, profit guidance
Aug 24Returns At Integra LifeSciences Holdings (NASDAQ:IART) Appear To Be Weighed Down
Aug 23Integra LifeSciences founder/former CEO dies
Aug 16Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: IARTDie kurzfristigen Aktiva des Unternehmens ($1.4B) übersteigen seine kurzfristigen Passiva ($302.4M).
Langfristige Verbindlichkeiten: IARTDie kurzfristigen Vermögenswerte des Unternehmens ($1.4B) decken seine langfristigen Verbindlichkeiten ($2.2B) nicht.
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: IARTDie Nettoverschuldung im Verhältnis zum Eigenkapital (73.9%) wird als hoch angesehen.
Schulden abbauen: IARTDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 99.1% auf 116.3% gestiegen.
Schuldendeckung: IARTDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (7%) gedeckt.
Zinsdeckung: IARTDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (6.9x Coverage) gut gedeckt.